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Abstract
In contrast to calcitonin which is primarily synthesized in
the thyroid, procalcitonin is a prohormone which is syn-
thesized in many different tissues of infected organs. To
diagnose mild, localized, or early infections an assay
needs to have a functional assay sensivity of approxi-
mately 0.02 mg/L. We demonstrated that procalcitonin
modifies the outcome of respiratory infections with
regard to minimizing the use of antibiotics and duration
of antibiotic treatment. High concentrations, especially
over time, indicate high risk of a severe outcome. In this
respect, procalcitonin is superior to other infection mark-
ers, such as C-reactive protein. High procalcitonin levels
can also be found in non-bacterial diseases, such as
malaria, severe trauma, burns, and medullar carcinoma
of the thyroid. Procalcitonin, as a marker, has improved
the diagnosis of bacterial infections. However, procalci-
tonin needs to be used in conjunction with other labo-
ratory markers, clinical examination, and medical history.
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What is procalcitonin?
Procalcitonin is the pro-hormone of calcitonin w1x. The
mature calcitonin hormone is only produced in thyroid C
cells and the relatively few neuroendocrine K cells of the
lung w2x. In the past, calcitonin was believed to control
calcium balance and regulate bone metabolism w2x, but
is known today that neither complete thyroidectomy with
removal of all C cells nor a medullar thyroid carcinoma
with C cell overproduction result in relevant changes of
calcium concentrations or bone density. This suggests
that mature calcitonin does not (no longer) have an
essential physiological function in humans w3, 4x.
Procalcitonin, on the other hand, seems to play a more
important role. In healthy humans, synthesis of procal-
citonin is suppressed. Experimental studies have shown,
that bacterial toxins and inflammatory mediators stimu-
late an ectopic, ubiquitous expression of calcitonigen,
followed by procalcitonin secretion w5, 6x. In contrast to
the localized production of calcitonin, procalcitonin,
when stimulated by a bacterial infection, is mainly pro-
duced in parenchymatic organs and differentiated body
cells. Figure 1 shows a schematic comparison between
regulated secretion (in case of mature calcitonin following
endocrine stimulation) and constitutive (non-regulated)
secretion (in case of procalcitonin following stimulation
by bacterial endotoxins). During this process, blood con-
centrations of procalcitonin can multiply several 100,000
times w7x. The procalcitonin increase during an infection
can be induced directly by microbial toxins (e.g., endo-
toxins), or indirectly by humoral or cell induced defense
reactions (e.g., interleukin-1b, interleukin-6, or tumor-
necrosis-factor-a). Production can be attenuated by
cytokins, which are, e.g., produced in viral infections
(such as interferon g) w6x.
Leucocytes produce procalcitonin only in small
amounts and temporarily while differentiating frommono-
cytes into macrophages w8x. This explains why procalci-
tonin blood concentrations found in sepsis patients
remain unchanged and high following chemotherapy and
complete eradication of leukocytes. White blood cells are
therefore not the main source of procalcitonin produc-
tion. In fact, parenchymatic cells (e.g., liver, fat tissue,
and muscle), the larges tissue mass, are the main source
of procalcitonin production in sepsis.
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Figure 1 Schematic of procalcitonin production (constitutive versus regulated procalcitonin secretion).
Figure 2 Sensitivity of different procalcitonin assays and cut-
off ranges for diagnosis of bacterial infection and indication
of antibiotic treatment prior to situation demanding treatment
(outpatient treatment to intensive care). RTsrespiratory infec-
tion, PCTsprocalcitonin, COPDschronic obstructive pulmonary
disease.
Procalcitonin measurements
Diagnostic accuracy of procalcitonin and optimal cut-off
ranges are largely determined by the sensitivity of the
assay. Figure 2 lists cut-off ranges for procalcitonin, and
the likelihood, with which a respiratory infection has a
bacterial etiology. A summary of assays used and their
respective sensitivities is also provided. These cut-offs
have to be adjusted to the treatment situation (family
physician’s office, emergency room, intensive care unit).
Ideally, an ultrasensitive assay capable of reliably detect-
ing values in healthy individuals should be used. Such
manual assays have been available temporarily, and
showed promising results w1, 9, 10x. Incomprehensibly,
these assays were not developed further, or they were
blocked due to patent protection issues. The Kryptor
PCT Assay (Brahms, Hennigsdorf, Germany), which is
less sensitive, was evaluated in a number of intervention
studies w11–15x. This assay is commercially available,
automated, and has a functional assay sensitivity of
0.06 mg/L, which is 3–5 times higher than that of healthy
individuals w9x. The assay duration is 19 min, with results
being available within one hour in routine clinical settings.
The volume of plasma needed is only 20–50 mL w16x. A
comparable assay is available from other manufacturers
(e.g., VIDAS, bioMe´rieux, Marcy l’e´toile, France). The
first commercially available assay was the LUMItest
PCT (Brahms, Hennigsdorf, Germany), which was mar-
keted in the 1990s, predominantly in intensive care units.
With a functional sensitivity of ;0.3 bis 0.5 mg/L this
assay can, however, only measure strongly elevated pro-
calcitonin concentrations. Its use is therefore restricted
to the diagnosis of sepsis in the setting of an intensive
care unit. The manual assay is, however, not suitable for
24 h emergency operations. For less strongly elevated
concentrations, which are often encountered in emergen-
cy room settings and in the outpatient setting, as well as
in beginning and localized infections, the sensitivity of
this assay is, however, insufficient. This has resulted in
confusing data in the literature. The advantage of a col-
orimetric ‘‘bedside’’ test (PCT-Q, Brahms, Hennigsdorf,
Germany) is that procalcitonin values are obtained within
30 min. Unfortunately though, this assay is only a semi-
quantitative, and has insufficient sensitivity to be re-
commended w18x.
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Procalcitonin in sepsis diagnosis
The diagnostic reliability of procalcitonin was at first
propagated in cases of sepsis. In sepsis, procalcitonin
blood concentrations increase more than 100,000-fold,
and often correlate with the severity of the disease and
its mortality w7, 19, 20x. Several studies have shown that
procalcitonin has a good diagnostic reliability in sepsis
diagnosis, which exceeds other infection markers (e.g.,
C-reactive protein or leucocyte count) w7, 21–23x. The
cut-off range, which was both sensitive and specific for
sepsis diagnosis, was determined to be 0.5–1.0 mg/L w7,
20x. The diagnostic reliability of a clinical model for sepsis
diagnosis, in particular, could be significantly improved
by procalcitonin w24x.
Results of all studies were recently summarized in two
systematic overviews and meta-analyses w25, 26x, where
a sensitivity of 88% (95% CI, 80%–93%), was listed for
procalcitonin, compared to 75% (95% CI, 62%–84%) for
C-reactive protein. Specificity for procalcitonin was 81%
(95% CI, 67%–90%) compared with 67% (95% CI,
56%–77%) for C-reactive protein w25x. Two other recent
meta-analyses, however, obtained disappointing results
regarding the reliability of procalcitonin in diagnosing
sepsis or bacteremia w27, 28x. It has to be noted, though,
that observational studies and meta-analyses are biased
by choice of procalcitonin assay used, clinical situation,
focus of infection, and particularly the gold standard,
which separates the diagnosis of sepsis versus non-
infectious SIRS and is particularly problematical or even
non-existing w29x. It is often forgotten that sepsis is not
a diagnosis, but a syndrome. When using biomarkers
though, optimal performance can only be achieved after
the treating physician has determined the origin and kind
of infection, based on medical history and examination
of the patient. Particular advantages of using the infec-
tion marker procalcitonin versus the inflammation marker
C-reactive protein, as a diagnostic marker of bacterial
infections are its higher specificity, faster kinetics, and
the only minimal effects a steroid therapy has on pro-
calcitonin levels.
Furthermore, differentiation of pneumonia from differ-
ent forms of differential diagnoses that are accompanied
by infiltration in the X-ray image, can be difficult. It was
shown that in these cases, the diagnostic reliability of
procalcitonin exceeded that of clinical parameters (e.g.,
body temperature) and C-reactive protein or leukocyte
count by far. Again, a significant improvement of the clin-
ical model by procalcitonin could be achieved w23x.
Procalcitonin does not seem to be a valuable diagnos-
tic marker in ventilation associated pneumonia (VAP),
since an existing VAP could not be predicted in one study
by procalcitonin concentrations (J. Chastre, personal
information). VAP is an infection with relatively low-viru-
lent pathogens (e.g., P. aeruginosa), which results in rel-
atively mild infections causing low signals. It is, however,
a life-threatening inflammation, due to its ‘‘Background
Noise’’, the severity of SIRS and its comorbidity. Con-
sequently, the signal-to-noise-ratio for procalcitonin is
unfavorable for the diagnosis of VAP.
Procalcitonin and antibiotic guidance in
respiratory infections
Respiratory infections are the most common reasons for
sepsis in humans w7x. 75% of all antibiotics worldwide
are prescribed for respiratory infections, even though
most of them are of viral origin. Unnecessary antibiotic
therapies are the main reason for increasing antibiotic
resistances. A reduction of unnecessary antibiotic ther-
apies would result in cost savings, less side effects, and
less resistances to antibiotics. In order to restrict antibi-
otic therapies, fast and accurate differentiation between
clinically relevant bacterial and self-limiting viral infec-
tions is crucial. A clinical examination and/or measure-
ment of inflammation parameters, such as C-reactive
protein or leukocyte count are usually of little benefit,
since lung inflammation can be a result of a bacterial or
viral respiratory infection, the symptoms of which often
overlap strongly. Due to its superior diagnostic value in
the diagnosis of bacterial infections, procalcitonin guided
antibiotic therapy is a major progress.
In the ProResp study, we could show that procalcito-
nin, when measured using the highly sensitive Kryptor
assay, can identify bacterial respiratory infections, which
require antibiotic treatment w11x. Depending on the pro-
calcitonin concentration, either a variable antibiotic treat-
ment or none at all was recommended (Figure 3) w14x.
Procalcitonin guided antibiotic therapy resulted in a sig-
nificant reduction of antibiotic prescriptions by 50%. The
most considerable reduction of antibiotic prescriptions
was observed in patients suffering from acute bronchitis
and from acute exacerbation of a chronic bronchitis. High
procalcitonin concentrations were observed in most
pneumonia patients. This supports the theory that the
majority of pneumonia cases is of bacterial etiology.
Therefore, antibiotic therapy should be the initial treat-
ment of choice in most cases of pneumonia. The rec-
ommended duration of such an antibiotic therapy is,
however, largely unclear. Depending on the pathogen,
7–21 days of antibiotic therapy are recommended in
guidelines, but the optimal duration of therapy was never
studied extensively w30x. Many guidelines recommend an
adjustment of antibiotic treatment duration to the spec-
trum of pathogens. In most cases (70%!) the pathogen
remains, however, unknown, even after use of invasive
diagnostic procedures Using the biomarker in the Pro-
CAP study, antibiotic treatment duration of severe cases
with septic pneumonia requiring hospitalization could be
reduced to -6 days in the procalcitonin guided group,
compared to 13 days in the control group w31x.
The ProCOLD study reported that procalcitonin guided
antibiotic treatment is also suitable for patients suffering
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Figure 3 Algorithm for procalcitonin guided antibiotic therapy. Procalcitonin concentrations determine if and to which degree anti-
biotic therapy is either advised against strongly or less strongly (procalcitonin -0.1 ug/L or -0.25 mg/L, respectively), or if it is
preferred or strongly recommended (procalcitonin )0.25 mg/L or )0.5 mg/L, respectively). For severely ill patients, antibiotic therapy
may be considered according to pre-defined criteria, even if procalcitonin levels are initially low. During the course of antibiotic
therapy, repeated procalcitonin measurements are needed in order to stop treatment using the same cut-off values.
PCTsProcalcitonin; COPDsChronic obstructive pulmonary disease; PSIsPneumonia Severity Index; CURB65sConfusion, Urea,
Respiration rate, Blood pressure, Age )65; BOOPsBronchiolitis Obliterans Organizing Pneumonia, SCLCsSmall Cell Lung Cancer;
SIRSsSystemic Inflammatory Response Syndrome, ARDSsAcute Respiratory Distress Syndrome.
from decreased lung reserve, i.e., patients with acute
exacerbation of chronic bronchitis. For these multimorbid
patients with impaired lung function, medium-term and
long-term outcomes are most important. These out-
comes were not affected by the reduction of antibiotics
given, as demonstrated by the same relapse rate in both
groups within a six-month period w15x.
Antibiotic prescriptions for respiratory infections are
still predominantly prescribed in family physician practic-
es. In another study conducted in this setting, which
included patients with upper and lower respiratory infec-
tions, procalcitonin guided antibiotic use was reduced by
75% w13, 32x. This was the first ‘‘non-inferiority’’ study,
which did not investigate antibiotic use, but patient safety
as a primary outcome.
Our concept was confirmed in a pilot ‘‘PROSEP’’ study
for infections in intensive care units by a group from
Geneva w33x, which reduced the average antibiotic treat-
ment duration from 10 to 6 days. As an incidental finding,
patients could also be dismissed from the intensive care
unit one day early, which is of socioeconomic interest.
These different studies, including their results, are
summarized in Figure 4. A multicenter study investigating
procalcitonin guided antibiotic therapy and its duration is
currently being conducted with more than 1350 patients
in various Swiss hospitals w14x. This study also evaluates
important prognostic factors, and other biomarkers.
Procalcitonin as diagnostic marker in
other infections
Conventional laboratory diagnostic infection markers and
clinical examinations are of limited help in determining
bacterial etiology, not only in respiratory infections, but
also in infections of other organ systems. Even though
positive blood cultures of a typical pathogen are very
specific, their sensitivity is low, and results are often
obtained as late as two to three days later.
In several other infections, better diagnostic reliability
has already been shown for procalcitonin. Procalcitonin
is e.g., a more accurate infection marker in the differen-
tiation of viral and bacterial meningitis in children as well
as adults w34, 35x. Other markers such as glucose, pro-
teins, cell count in liquor as well as C reactive protein
showed more overlap and were less reliable. In a non-
randomized pilot study, procalcitonin guided antibiotic
therapy was successful w36x.
It was shown during diagnosis of a pancreatitis that
procalcitonin concentrations were relatively low in
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Figure 4 Summary of five published randomized intervention studies on procalcitonin guided antibiotic therapy in respiratory infec-
tions and sepsis.
Diagnosis, name, setting, number of patients, and extent of antibiotic reduction as main result are listed for each study.
patients with edematous or toxic pancreatitis, and high
in patients with infectious pancreatitis w37x. This could be
particularly helpful when monitoring patients requiring
surgical intervention due to secondary infection of the
initial focus of infection. More conclusive studies are
needed to answer this question.
In pyelonephritis, procalcitonin is a helpful marker of
the severity of this disease w38x. This was mostly studied
in children, where procalcitonin concentrations correlated
with the severity of pyelonephritis, particularly with renal
scarring w39x, contrary to C-reactive protein, interleukin-
6, and other markers.
Diagnosis of endocarditis may be clinically challenging
as well, particularly due to the variability of its presenta-
tion. Echocardiography could, e.g., detect only 43 out of
500 patients suffering from infectious endocarditis w40x.
In one of the studies procalcitonin was the only signifi-
cant independent predictor of infectious endocarditis,
which was contrary to other infection markers. The diag-
nostic reliability of procalcitonin in this study was com-
parable to that of natriuretic peptide type B in the
diagnosis of cardiac insufficiency w41x. Caution is, how-
ever, indicated in cases of subacute endocarditis ‘‘lenta’’
where procalcitonin concentrations are often only slightly
elevated.
There are also indications that procalcitonin allows bet-
ter differentiation between bacterial arthritis and gout or
rheumatoid arthritis w42x. A new observation study de-
monstrated a very high diagnostic reliability of procalci-
tonin in the differential diagnosis of bacterial arthritis
versus arthritis of non-bacterial etiology w43x. A cut-off of
0.1 mg/L was associated with maximum diagnostic reli-
ability. Therefore, a highly sensitive assay for the analysis
of procalcitonin is required here as well. To date, the
diagnostic value of procalcitonin in osteomyelitis has only
been investigated in one study. In this study, procalcito-
nin concentrations were elevated in only a little more than
half of the patients, but values were obtained using a
semiquantitative assay w44x. The representative character
of these study results is therefore questionable, particu-
larly since only moderately elevated procalcitonin con-
centrations are expected in osteomyelitis, and similar
studies will have to be conducted using a more sensitive
assay.
One study reviewed the benefit of procalcitonin in the
differentiation of patients with fever and infectious growth
of typical skin pathogens (coagulase negative staphylo-
cocci) from simple blood contamination w10x. Procalci-
tonin, when the measurement was repeated using a
highly sensitive assay, allowed the differentiation of
patients with true sepsis from those where contamination
of the cultures had occurred. Interestingly, procalcitonin
concentrations in septic patients were elevated even
before the clinical manifestation of fever, which is likely
caused by colonization of the vein catheter with virulent
pathogens, which will subsequently lead to clinical
manifestation.
Data collected in gynecology and obstetrics measured
procalcitonin associated with rupture of the membranes.
Procalcitonin was elevated in the mother’s blood after
premature rupture of the membranes, compared with
women in the same gestational week whose membranes
had not ruptured prematurely. A large overlap was, how-
ever, noted w45x. The etiology of premature membrane
rupture differs, however, widely, and it is not always of
infectious nature, which possibly accounts for the large
data variability. Both procalcitonin and C-reactive protein
were poor predictors of congenital infection or chorion-
amnionitis w45x. But the relevance of this study is limited,
due to the usage of an insensitive test.
Interestingly, procalcitonin is present in breast milk.
This seems to be the only place where procalcitonin is
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Table 1 Caveats of procalcitonin.
Reasons for ‘‘falsely’’ high PCT concentrations (high values in
the absence of apparent bacterial infection):
• Physiological in newborns during initial phase
• ARDS (acute respiratory distress syndrome)
• Malaria
• Systemic fungal infections (very variable data)
• Severe trauma
• Following major surgeries w57x
• Severe burns or heat stroke
• Pneumonitis
• Calcitonin producing tumors (such as medular thyroid car-
cinoma, carcinoid, small cell carcinoma of the lung with
paraneoplastic hormone production)
• ‘‘Cytokine’’ storm, e.g., following administration of mono-
clonal or polyclonal antithymocyte globulin in the treatment
of rejection reactions or associated with familiar
Mediterranean fever w6, 8x.
Reasons for ‘‘falsely’’ low PCT concentrations using an insen-
sitive assay (low concentrations in the presence of bacterial
infection):
• Very early during the course of an infection w11x.
• Strongly localized infection (e.g., abscess)
• Subacute endocarditis
produced in healthy women without being triggered by
an infection. Postpartum levels are further elevated, with
a maximum on day 2, and drop subsequently. Any con-
clusion regarding the underlying biological reason is
speculative at current time. Procalcitonin, which has anti-
inflammatory properties, could play a role in the activa-
tion of the immunosystem of the newborn w46x. In one
patient who developed mastitis, concentrations dropped
initially, and increased again on the sixth day postpartum
w46x. High levels of procalcitonin are physiologically
found in newborns, possibly due to the bacterial coloni-
zation of the newborns’ intestines, which are sterile right
after birth. Since levels are even more enhanced in new-
born sepsis, procalcitonin remains a helpful marker in the
diagnosis of newborn sepsis, once cut-off values are
adjusted accordingly w47, 48x.
A recent study investigated if differentiation between
an infected and non-infected diabetic foot could be facil-
itated by procalcitonin or C-reactive protein. The highest
diagnostic reliability in this study was found for a com-
bination of procalcitonin and C-reactive protein. The
golden standard used was, however, the clinical deter-
mination of infection, which is problematic in this and all
other observation studies w49x.
For other infections, such as simple urinary tract infec-
tions, diverticulitis, adnexits, appendicitis, and a number
of others, no data are available at this time regarding the
diagnostic relevance of procalcitonin.
Procalcitonin as prognostic marker in
other infections
The prognosis of pneumonia patients is of special impor-
tance, since it determines where and how intensively the
patient will have to be treated. The severity of pneumonia
is commonly classified into five classes according to the
pneumonia severity index (PSI), with mortality gradually
increasing from class I with -1% to class V with up to
30% w50x. The prognostic relevance of procalcitonin is
superior to that of other markers like C-reactive protein
or leukocyte count. Neither C-reactive protein and leu-
kocyte count can differentiate between a class I and a
class V pneumonia. Even though procalcitonin concen-
trations measured at the onset of the disease increase
with higher pneumonia severity scores, we found that
these values overlap significantly w23x. Prognosis was
good for patients with initial PCT values below
0.1–0.25 mg/L. More significant information is obtained
from the course of procalcitonin. Prognosis is poor for
increasing values or the absence of a decline, while rap-
idly decreasing values indicate a favorable prognosis w24,
51x. The course of procalcitonin is prognostically also rel-
evant in the case of VAP, which contradicts its above-
mentioned restricted diagnostic reliability. For a
procalcitonin concentration of )0.5 mg/L on day 7 a
poor outcome could be detected with a sensitivity of
90% and a specificity of 88% w52x.
In patients with COPD exacerbations, a procalcitonin
concentration )0.25 mg/mL was predictive of longer
hospitalization and transfer to an intensive care unit, it
had, however, no prognostic value regarding timing of
further exacerbations and long-term outcome w53x.
Precautions for the use of procalcitonin
Results for procalcitonin, like those for all diagnostic
markers, of course can be falsely positive or negative
w54x.
Table 1 lists the main reasons for falsely high or low
procalcitonin concentrations. Falsely high procalcitonin
concentrations can, e.g., occur in (pro)-calcitonin pro-
ducing tumors, such as medullary thyroid carcinoma or
small cell lung carcinoma, in malaria, in newborns imme-
diately postpartum, or temporarily following surgeries,
inflammations, trauma, or burns. It has also been spec-
ulated that procalcitonin concentrations in these latter
situations are not ‘‘falsely’’ high, but indicative of a true
bacterial infection, caused by the omnipresent and viru-
lent intestinal flora, which is translocated through the
intestinal wall due to the lack of intestinal perfusion,
thereby providing an early sign of a developing bacterial
complication w55, 56x. The course of procalcitonin con-
centrations remains particularly significant for postoper-
atively high levels. During an uneventful postoperative
course, procalcitonin concentrations drop rapidly from
the second to the third postoperative day. Persistently
high values indicate an infection w57x. As mentioned
above, the diagnosis of sepsis in newborns requires the
adjustment of the cut-off ranges.
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Main reasons for falsely low procalcitonin concentra-
tions are strongly localized infections, such as abscess
or lung empyema, presumably due to the small amount
of infected tissue mass. Furthermore, procalcitonin con-
centrations can be low during the early phase of an infec-
tion (-6 h). In case of a clinically suspected bacterial
infection with low procalcitonin concentrations, the assay
should be repeated within 6–24 h, so that a possible
delayed increase is not missed.
In summary, it is absolutely essential that procalcitonin
levels are always interpreted within the clinical context,
based on a detailed medical history and prior clinical
examination.
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